Thursday, October 25th, 8:30-9:55am
Affordability is a central focus of China’s healthcare reforms. What changes in healthcare reform and the private payor markets might occur that can assist with affordability and access? Will new medicines become affordable in China, and can new technologies and developments help create less expensive medicines? What does the looming expansion of the Essential Drug List and National Reimbursement Drug List mean for both Chinese and Western companies? Experts and representatives from the Chinese Government will tackle reimbursement, healthcare reform and private insurance issues.
- George Baeder, Senior Vice President, Asia Pacific Consulting and China Commercial, Quintiles
- Joseph Cho, Managing Director, RDPAC
- John V. Oyler, Founder and CEO, BeiGene
- Qiao Shanbo, General Manager, PICC Health Insurance Shanghai
- Harald Sprenger, Director, Market Access Strategy & Private Insurance, Roche
George leads Quintiles Consulting Asia/Pacific and the firm’s Commercial business in China, based in Shanghai. He has spent over 30 years in Asia working with leading Asian and Western firms to build profitable high-growth businesses in the region’s most challenging and complex markets. He is widely considered to be a thought leader in the industry, having worked on the cutting edge of innovative approaches to market entry, R&D, access and new commercial models - helping clients take decisive moves ahead of competitors.
His life science consulting in began with as an advisor on the first pharma joint venture in China set up by an Astra-led consortium of five Swedish companies in Wuxi. Since then he has work with all of the leading Western biopharma firms both in China and across the Asian region. George combines strong strategy skills and analytics with an intensely practical focus on implementation.
Prior to joining Quintiles Consulting, George led the Monitor Group’s Life Science practice in Asia for nine years. In the early part of his career, George built two professional services firms that he subsequently sold to leading global players in their respective fields. He then spent three years as an investment banker with working on Asian-focused life science transactions.
George was educated in Economics at Lafayette College and then studied China’s economic development at Oakland University and Taiwan Normal University.
John V. Oyler
John Oyler is a serial entrepreneur with a track record of success. John has raised over $270 million in capital, each round providing positive returns. John is most known for building highly functional, passionate, world-class organizations.
Currently, John is Founder & CEO of BeiGene. BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs that will address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific region. It was founded by Dr. Xiaodong Wang, Head of The National Institute of Biologic Sciences in Beijing and Member of National Academy of Sciences, USA; Dr. Peter Ho, Former VP of Oncology Development at Johnson & Johnson; and Dr. Pearl Huang, Former VP Integrator and Head of Biomarker Discovery and Early Development Strategy for Oncology at Merck.
John has also started several companies such as BioDuro (sold to PPD), a 670+ person research company in Beijing that was a leader in its vision and ability to successfully undertake in fully integrated programs; Galenea , a private drug discovery company developing drugs for CNS and respiratory disease; Genta (GNTA), a publicly traded company which later grew to a market capitalization of over $US1.6 billion; and Telephia, an information services company for the telecommunications industry that was purchased by Nielsen for just under $500 million.
He spent four years at McKinsey where he spent 1992-3 working in China. He holds a BS from MIT and an MBA from Stanford.
Qiao Shanbo, MHP, serves as the general manager of the PICC Health Insurance Company Limited, Shanghai Branch, and has over a decade of experience in the administration of private health insurance. From 2008 to 2011, he worked as the general manager of product development in PICC’s head health office, and from 2005-2007 he was the deputy general manager of the PICC Shanghai branch. He has also worked as the general manager of China Pacific Life Insurance’s health department and as a product manager at Pingan Life Insurance Company. He holds a BS in mathematics from Zhengzhou University, and a postgraduate degree in business administration from Huanghe University.